Group 1 - The core point of the news is that Hualan Co., Ltd. experienced a decline of 5.14% in its stock price, reaching 34.51 CNY per share, with a total market capitalization of 5.667 billion CNY [1] - Hualan Co., Ltd. is primarily engaged in the research, production, and sales of packaging materials for injectable drugs, with its main revenue sources being film-coated rubber stoppers (49.07%) and conventional rubber stoppers (48.50%) [1] - The company was established on June 4, 1992, and went public on November 1, 2021 [1] Group 2 - From the perspective of major fund holdings, one fund under Dacheng Fund has a significant position in Hualan Co., Ltd., with 620,000 shares held, accounting for 3.29% of the fund's net value [2] - The Dacheng Growth Mixed Fund (160926) has reported a floating loss of approximately 1.1594 million CNY due to the decline in Hualan's stock price [2] - The fund has achieved a year-to-date return of 25.68% and a one-year return of 27.96%, ranking 3506 out of 8160 and 3478 out of 8021 respectively in its category [2]

联席主承销商：国信证券股份有限公司 广州必贝特医药股份有限公司 保荐人（主承销商）：中信证券股份有限公司 必贝特是一家以临床价值为导向、专注于创新药自主研发的生物医药企业。 必贝特实际控制人为钱长庚，无控股股东。截至招股意向书签署日，钱长庚直接持有必贝特15.2840%的股份，是必贝特的第一大股东，同时通 过担任广州药擎执行事务合伙人控制必贝特8.5899%的股份。 钱长庚，1955年出生，美国国籍，拥有中国境内永久居留权。 发行情况： | | 股票代码 | 688759 | 股票简称 | 必见特 | | --- | --- | --- | --- | --- | | | 申购代码 | eastmoney 787759 | 上市地点 | 上海证券交易所科创板 om | | | 发行价格(元假) | 17.78 | 友行市盈率 | | | | 市需率参考行业 | 医药制造业 | 参考行业市盈率(最新) | 31.83 | | | 友行面值(元) | 1 | 买际要集资 高额(亿元) | 16.00 | | 发行状况 | 网上发行日期 | 2025-10-17 (周五) | 网下配售目期 | 2025-10-17 ...

Group 1: New Stock Subscription - Bibet - Bibet is a biopharmaceutical company focused on innovative drug development, particularly in oncology, autoimmune diseases, and metabolic diseases [2] - The company has a market capitalization of 6.401 billion yuan and an issue price of 17.78 yuan per share, with an institutional offering price of 18.12 yuan per share [5] - Bibet's primary research pipeline includes one approved innovative drug, BEBT-908, and several others in various clinical trial phases [6][8] - The company plans to invest 9.49 billion yuan in new drug research and development, 5.55 billion yuan in a research center and production base, and 5 billion yuan to supplement working capital [5] Group 2: Financial Performance and Risks - Bibet - Bibet has not generated any revenue and has reported continuous net losses since its establishment, with losses of 1.88 million yuan, 1.73 million yuan, and 0.56 million yuan in recent years [9] - The company is heavily reliant on the commercialization of BEBT-908, which is expected to be conditionally approved for market by June 30, 2025 [8] - The company faces risks related to the commercialization of its products, including market access, insurance inclusion, and sales network establishment [8] Group 3: New Stock Listing - Daosheng Tianhe - Daosheng Tianhe is a national high-tech enterprise specializing in the research, production, and sales of new materials, particularly epoxy resins and polyurethane [10] - The company has a market capitalization of 3.943 billion yuan and an issue price of 5.98 yuan per share, with an institutional offering price of 6.32 yuan per share [13] - Daosheng Tianhe is recognized as a leading supplier of wind turbine blade materials and has established stable relationships with major industry players [15][16] Group 4: Financial Performance and Market Position - Daosheng Tianhe - The company reported revenues of 3.436 billion yuan, 3.202 billion yuan, and 3.238 billion yuan from 2022 to 2024, with net profits of 110 million yuan, 155 million yuan, and 155 million yuan respectively [16] - Daosheng Tianhe's performance has shown volatility, influenced by market competition, seasonal fluctuations, and raw material price changes [16] - The company has obtained 69 patents, including 38 invention patents, enhancing its competitive edge in the market [16]

Group 1: New Stock Subscription - Bibet - Bibet (688759.SH) is a biopharmaceutical company focused on innovative drug development, particularly in oncology, autoimmune diseases, and metabolic diseases [1][4] - The company has a market capitalization of 6.401 billion yuan and an issue price of 17.78 yuan per share, with an expected price-to-earnings ratio of 31.83 [4] - Bibet's research pipeline includes one approved innovative drug, BEBT-908, and several others in various clinical trial phases, with a significant focus on unmet clinical needs [5][6][7] Group 2: Financial Performance and Funding - Bibet has reported net losses of 0.0188 billion yuan, 0.0173 billion yuan, and 0.0056 billion yuan over the past three years, indicating ongoing financial challenges [8] - The company plans to allocate 9.49 billion yuan (47.35%) of its raised funds to new drug research and development, 5.55 billion yuan (27.71%) to the construction of a research center, and 5.00 billion yuan (24.94%) for working capital [4] Group 3: New Stock Listing - Daosheng Tianhe - Daosheng Tianhe (601026.SH) is a national high-tech enterprise specializing in the research, production, and sales of new materials, particularly epoxy resins and polyurethane [1][11] - The company has a market capitalization of 3.943 billion yuan and an issue price of 5.98 yuan per share, with a price-to-earnings ratio of 29.05 [11] - Daosheng Tianhe is recognized as a leading supplier of materials for wind turbine blades and has established stable relationships with major industry players [14][15] Group 4: Financial Performance and Market Position - Daosheng Tianhe's revenue for 2022, 2023, and 2024 was 3.436 billion yuan, 3.202 billion yuan, and 3.238 billion yuan, with net profits of 0.11 billion yuan, 0.155 billion yuan, and 0.155 billion yuan respectively [15] - The company has been recognized as a national-level "little giant" enterprise and has obtained 69 patents, including 38 invention patents [15]

Company Overview - Guangzhou Bibetter Pharmaceutical Co., Ltd. is a biopharmaceutical company established in 2012, focusing on innovative drug research and development with a clinical value orientation [4] - The company specializes in major disease areas such as tumors and metabolic diseases, leveraging its core technology platform for continuous development of first-in-class drugs and innovative medicines addressing unmet clinical needs [4][11] Research and Development Pipeline - The company has established a diverse and differentiated R&D pipeline, having obtained over 30 clinical approvals, with one class 1 innovative drug already on the market and two others in phase III clinical trials [5][21] - The core product, BEBT-908, is a globally first-in-class HDAC/PI3Kα dual-target anti-tumor drug, approved for treating relapsed or refractory diffuse large B-cell lymphoma, with other indications in phase II clinical trials [5][25] - The company is also focusing on next-generation small nucleic acid (siRNA) drug development, having established three proprietary delivery systems with global intellectual property rights [6][22] Financials and Investment - The company has invested significantly in R&D, with expenditures of approximately 166.74 million yuan in 2022, 157.65 million yuan in 2023, and projected 120.29 million yuan in 2024 [17] - The funds raised from the IPO will primarily be used to accelerate the clinical progress of the R&D pipeline, enhance commercialization capabilities, and expand the product line [26][30] Market Position and Strategy - The company aims to become a globally influential innovative drug developer in major disease areas, focusing on deepening independent R&D, accelerating commercialization, and expanding into global markets [19] - The competitive advantages include innovation-driven development, strong R&D capabilities, a broad product pipeline, and significant market potential for approved and core products [20][25] Regulatory Environment - The implementation of the drug marketing authorization holder (MAH) system is seen as a favorable policy for the company, allowing it to focus resources on core R&D activities [25] - The company meets the listing standards for the Sci-Tech Innovation Board, having at least one core product approved for clinical trials and a projected market value of no less than 4 billion yuan [28][29]

Core Viewpoint - 博瑞医药 announced the termination of its 2024 A-share issuance plan, which was intended to raise 500 million yuan, citing market conditions and company circumstances as reasons for the withdrawal [1][3]. Group 1: Termination of A-share Issuance - The A-share issuance plan was approved by the board and shareholders in May 2024, with the actual controller, Yuan Jiandong, set to fully subscribe at a price of 22.36 yuan per share [3]. - The plan faced delays and revisions over the course of a year, with the company ultimately retracting its application before the Shanghai Stock Exchange could issue a review inquiry [3][4]. Group 2: Stock Price Volatility - During the planning period for the issuance, the company's stock price fluctuated significantly, initially around 30 yuan and peaking at 122.59 yuan in early August 2025, before dropping to 53.25 yuan by mid-October, representing a 53.04% decline from its peak [4][5]. - Despite the stock price drop, the company's rolling P/E ratio remained high at 243.45, compared to the industry average of 30.82 [5]. Group 3: Financial Performance - From 2021 to 2024, the company's revenue increased from 1.052 billion yuan to 1.283 billion yuan, but net profit declined for four consecutive years, reaching 189 million yuan in 2024 [6]. - In the first half of 2025, revenue fell by 18.28% year-on-year to 537 million yuan, with net profit plummeting by 83.85% to 17.17 million yuan, primarily due to a 70.08% drop in antiviral raw material revenue [6][7]. Group 4: Future Financing Plans - Following the termination of the A-share issuance, the company is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international financing capabilities [8]. - The company aims to consider shareholder interests and market conditions when determining the timing and details of the H-share issuance, although uncertainties remain regarding the approval process [8]. Group 5: Company Strategy and Market Position - 博瑞医药 is transitioning from a traditional chemical pharmaceutical company to an innovative drug enterprise, focusing on the development of innovative drugs, particularly in the weight loss sector [8]. - The termination of the A-share issuance may delay the company's progress in this area, but successful H-share issuance could provide necessary funding for innovation and commercialization efforts [8].

南方财经10月15日电，天眼查工商信息显示，近日，广生合癀（漳州）医药有限公司成立，法定代表人为黄晓航，注册资本5000万人民币，经营范围含药品 批发、食品销售、保健食品销售、食品互联网销售、特殊医学用途配方食品销售、化妆品批发、日用杂品销售、以自有资金从事投资活动等。股东信息显 示，该公司由广生堂（300436）以及片仔癀（600436）旗下福建片仔癀健康科技有限公司分别持股51%、49%。 | | 查公司 查老板 查关系 查风险 | | | --- | --- | --- | | 2 天眼查 都在用的商业直间工具 TlanYanCha.com 国家中小企业发展子基金旗下机构 | 广生合癢（漳州）医药有限公司 | (*) 天眼一下 | | 基本信息 12 | 经营风险 | 法律诉讼 | | 经营信息 公 | | --- | --- | --- | --- | --- | | 法定代表人 | | 黄 黄晓航 | 登记状态 ② | 存续 | | | | | 成立日期 | 2025-10-13 | | 统一社会信用代码 ② | | 91350603MAG18XPH9Y | 注册资本 ② | 5000万人民币 | ...

Group 1 - The core point of the news is that Hualan Co., Ltd. (华兰股份) is currently experiencing a decline in stock price, with a closing price of 37.26 yuan and a drop of 6.45%, resulting in a total market value of 6.118 billion yuan [1] - Hualan Co., Ltd. was listed on the Shenzhen Stock Exchange's ChiNext board on November 1, 2021, with an initial public offering (IPO) of 33.66667 million shares, accounting for 25% of the total share capital after issuance, at a price of 58.08 yuan per share [1] - The total amount raised by Hualan Co., Ltd. during the IPO was 1.955 billion yuan, with a net amount of 1.804 billion yuan, which exceeded the original plan by 1.254 billion yuan [1] - The company planned to use the raised funds for automation and intelligent factory renovation, research and development center construction, and to supplement working capital [1] - The issuance costs amounted to 151 million yuan, with the underwriting and sponsorship fees to Huatai United Securities Co., Ltd. being 133 million yuan [1] Group 2 - Hualan Co., Ltd. announced its 2024 annual equity distribution plan, which includes a cash dividend of 2 yuan for every 10 shares held and a capital reserve conversion of 3 shares for every 10 shares held [2] - The record date for the equity distribution is set for July 11, 2025, and the ex-dividend date is July 14, 2025 [2] - The trading date for the newly issued shares without restrictions will also begin on July 14, 2025 [2]

Core Viewpoint - Three new stocks from the Sci-Tech Innovation Board are set to be issued, with a total expected fundraising of 9.751 billion yuan [1][2]. Group 1: Company Summaries - **He Yuan Bio**: - Issuance date: October 14, 2025 - Total shares to be issued: 89.4514 million - Online issuance: 14.3120 million shares - Issuance price: 29.06 yuan - Company specializes in innovative biopharmaceuticals with a leading global plant bioreactor technology platform [1]. - Projected net profit for 2023 and 2024: -187 million yuan and -151 million yuan, respectively, with year-on-year changes of -30.22% and 19.04% [1]. - **Xi'an Yicai**: - Issuance date: October 16, 2025 - Total shares to be issued: 538 million - Online issuance: 53.78 million shares - The company focuses on the research, production, and sales of 12-inch silicon wafers in the semiconductor silicon materials sector [2]. - Projected net profit for 2023 and 2024: -578 million yuan and -738 million yuan, respectively, with year-on-year changes of -40.35% and -27.63% [2]. - **Bibet**: - Issuance date: October 17, 2025 - Total shares to be issued: 90 million - Online issuance: 14.4 million shares - The company is a biopharmaceutical firm focused on innovative drug development for major diseases such as cancer and autoimmune diseases [2]. - Projected net profit for 2023 and 2024: -173 million yuan and -55.9983 million yuan, respectively, with year-on-year changes of 8.27% and 67.59% [2].

武汉禾元生物科技股份有限公司 保荐机构（联席主承销商）：国泰海通证券股份有限公司 发行情况： | 殿票代码 | 688765 | 股票简称 | 禾元生物 | | --- | --- | --- | --- | | 申购代码 | 787765 | 上市地点 | 上海证券交易所科创板 | | 发行价格(元/股) | 29.06 | 发行市盈率 | | | 市盈率参考行业 | 医药制造业 | 参考行业市盈率(最新) | 32.08 | | 发行面值(元) | 1 | 实际募集资金总额(亿 元) | 66.99 | | 网上发行日期 | 2025-10-14 (周二) | 网下載雪目期 | 2025-10-14 | | 网上发行数量(股) | 14.312.000 | 网下配雪数量(股) | 57.658.846 | | 老股转让数量(股) | | 总发行数量(股) | 89.451.354 | | 申购数量上限(股) | 14.000 | 中签到款日期 | 2025-10-16 (周四) | | 网上顶格申购需配市值 (万元) | 14.00 | 网上申购市值确认日 | T-2 日(T:网上申购日) | | 网下申 ...